サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1605724

アンデルセン・タウィル症候群治療市場：治療タイプ別、薬剤クラス別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年

Andersen Tawil Syndrome Treatment Market, By Treatment Type, By Drug Class, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 392 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
アンデルセン・タウィル症候群治療市場：治療タイプ別、薬剤クラス別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年
出版日: 2024年11月28日
発行: AnalystView Market Insights
ページ情報: 英文 392 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

アンデルセン・タウィル症候群治療市場規模は2023年に17億6,523万米ドルとなり、2024年から2032年にかけてCAGR 7.2％で拡大

アンデルセン・タウィル症候群治療市場-市場力学

遺伝子治療の進歩と遠隔医療の拡大がアンデルセン・タウィル症候群治療市場の成長を促進

遺伝子治療の進歩と遠隔医療サービスの拡大が、アンデルセン・タウィル症候群治療市場を大きく押し上げています。米国遠隔医療近代化法（U.S. Telehealth Modernization Act）のようなイニシアチブに支えられた遠隔医療プラットフォームの導入により、遠隔地の患者の専門医療へのアクセスが増加しています。米国国立衛生研究所（NIH）のような機関は、アンデルセン・タウィル症候群を含む遺伝性疾患に焦点を当てた50以上の活発な研究を行い、標的療法を開発するための研究資金を提供しています。さらに、遠隔医療がヘルスケアシステムに統合されつつあることで、希少疾患患者の60％近くが移動の必要なく専門医に相談できるようになり、管理体制や治療プロトコールの遵守が向上しています。

アンデルセン・タウィル症候群治療市場-主要インサイト

弊社のリサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約7.2%のCAGRで毎年成長すると予測されています。

治療タイプ別では、2023年には薬物療法が最大の市場シェアを示すと予測されました。

薬剤クラス別では、2023年には炭酸脱水酵素阻害薬が主要タイプに

投与経路別では、経口投与が2023年の主要タイプです。

地域別では、北米が2023年の売上高でトップ

アンデルセン・タウィル症候群治療市場-セグメンテーション分析：

アンデルセン・タウィル症候群治療の世界市場は、治療タイプ、薬剤クラス別、投与経路、エンドユーザー、地域に基づいて区分されます。

市場は治療タイプによって2つのカテゴリーに分けられる：薬物療法と理学療法です。薬物療法は、心不整脈や周期性麻痺のような症状に直接対処するため、アンデルセン-タウィル症候群治療市場において最も高い優先順位を占めています。理学療法はそれに続くもので、長期的な管理と患者のQOLのために筋力と運動能力を向上させるという重要な役割を果たします。

市場は薬剤クラス別に3つに分類される：炭酸脱水酵素阻害薬、β遮断薬、カリウムサプリメントです。炭酸脱水酵素阻害薬は、周期性麻痺エピソードの管理に有効であることから優先的に使用されます。β遮断薬はアンデルセン-タウィル症候群でよくみられる不整脈に対処します。カリウムサプリメントは、低カリウム血症を改善し、患者の筋肉と心臓の機能を安定させるために不可欠です。

アンデルセン・タウィル症候群治療市場-地理的洞察

北米がアンデルセン・タウィル症候群治療市場を独占しており、その背景には強固なヘルスケアインフラと希少疾患研究への資金提供の増加があります。この地域は、米国国立衛生研究所（NIH）が支援する希少疾患臨床研究ネットワーク（RDCRN）のようなイニシアチブの恩恵を受けており、遺伝性疾患に関する70以上の共同研究を促進しています。米国では2023年、アンデルセン・タウィル症候群に伴う周期性麻痺への対処を目的とした新規カリウムチャネル調節薬の開発で、主要製薬企業とバイオテクノロジー企業が重要な提携を結ぶ。欧州では、欧州医薬品庁（EMA）が複数の治験薬に希少疾病用医薬品（オーファンドラッグ）の指定を行っています。アジア太平洋地域では、希少疾病治療法（Orphan Drug Act）が希少疾病治療開発を奨励している日本のような国々におけるヘルスケア意識の高まりと政府の支援が、市場の見通しを後押ししています。さらに、オーストラリアの著名なヘルスケアプロバイダーが遠隔医療プラットフォームを立ち上げたことで、特に地方における患者の専門医へのアクセスが向上し、より良い疾患管理が可能となっています。

アンデルセン・タウィル症候群治療市場-競合情勢：

アンデルセン・タウィル症候群治療市場は、大規模な研究開発投資と大手製薬企業の存在により、北米が主要地域となりつつあります。2023年には、米国を拠点とするバイオテクノロジー企業が、アンデルセン・タウィル症候群に関連する周期性麻痺の有望な治療法であるカリウムチャネル調節薬の開発を加速させるため、欧州企業との戦略的合併を発表しました。さらに、学術機関と産業界のリーダーとの共同研究により、新規遺伝子治療に焦点を当てた40以上の臨床試験が行われています。欧州も重要な役割を果たしており、複数の製薬会社がEMAから希少疾病用医薬品の指定を受け、この地域の競争力を高めています。一方、アジア太平洋地域では、日本企業が最近、希少遺伝性疾患を対象とした画期的な遺伝子治療プラットフォームを立ち上げ、市場での地位を高めています。遠隔医療プラットフォームの世界の普及と相まって、これらのイニシアチブは、アンデルセン・タウィル症候群治療市場のダイナミックで競争的な性質を裏付けています。

目次

第1章 アンデルセン・タウィル症候群治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 アンデルセン・タウィル症候群治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 アンデルセン・タウィル症候群治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 アンデルセン・タウィル症候群治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 アンデルセン・タウィル症候群治療市場情勢

  • アンデルセン・タウィル症候群治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 アンデルセン・タウィル症候群治療市場-治療タイプ別

  • 概要
    • 治療タイプ別：セグメントシェア分析
    • 薬物
    • 理学療法

第8章 アンデルセン・タウィル症候群治療市場-薬剤クラス別

  • 概要
    • 薬剤クラス別：セグメントシェア分析
    • 炭酸脱水酵素阻害剤
    • ベータ遮断薬
    • カリウムサプリメント

第9章 アンデルセン・タウィル症候群治療市場- 投与経路別

  • 概要
    • 投与経路別：セグメントシェア分析
    • 経口
    • 静脈注射

第10章 アンデルセン・タウィル症候群治療市場- エンドユーザー別

  • 概要
    • エンドユーザー別：セグメントシェア分析
    • 病院
    • 専門クリニック
    • 調査機関

第11章 アンデルセン・タウィル症候群治療市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋地域
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- アンデルセン・タウィル症候群治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Johnson &Johnson Services, Inc.
    • Merck &Co., Inc.
    • Mylan NV
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV4287

REPORT HIGHLIGHT

Andersen Tawil Syndrome Treatment Market size was valued at USD 1,765.23 Million in 2023, expanding at a CAGR of 7.2% from 2024 to 2032.

The Andersen-Tawil Syndrome Treatment Market focuses on therapeutic solutions for a rare genetic disorder characterized by periodic paralysis, cardiac arrhythmias, and distinctive physical features. Growing advancements in genetic research and precision medicine have fueled the development of targeted therapies, enhancing patient outcomes. Increasing awareness among healthcare professionals and improved diagnostic capabilities have contributed to the early detection of the syndrome, with nearly 70% of cases now identified through genetic testing. However, the high cost of treatment and limited availability of specialized healthcare facilities pose significant challenges. Market opportunities include the development of novel therapies and the expansion of telemedicine services to support remote patient management.

Andersen Tawil Syndrome Treatment Market- Market Dynamics

Advancements in Genetic Therapies and Telemedicine Expansion Propel Growth in the Andersen-Tawil Syndrome Treatment Market

Advancements in genetic therapies, coupled with the expansion of telemedicine services, are significantly boosting the Andersen-Tawil Syndrome Treatment Market. The implementation of telehealth platforms, supported by initiatives such as the U.S. Telehealth Modernization Act, has increased access to specialized care for patients in remote areas. Institutions like the National Institutes of Health (NIH) are funding research to develop targeted therapies, with over 50 active studies focusing on genetic disorders, including Andersen-Tawil Syndrome. Moreover, the growing integration of telemedicine into healthcare systems has allowed nearly 60% of rare disease patients to consult specialists without the need for travel, improving management and adherence to treatment protocols.

Andersen Tawil Syndrome Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.2% over the forecast period (2024-2032)

Based on Treatment Type segmentation, Medication was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Carbonic anhydrase inhibitors were the leading type in 2023

Based on Route of Administration segmentation, Oral administration was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Andersen Tawil Syndrome Treatment Market- Segmentation Analysis:

The Global Andersen Tawil Syndrome Treatment Market is segmented based on Treatment Type, Drug Class, Route of Administration, End-User, and Region.

The market is divided into two categories based on Treatment Type: Medication and Physical Therapy. Medication holds the highest priority in the Andersen-Tawil Syndrome Treatment Market, as it directly addresses symptoms like cardiac arrhythmias and periodic paralysis. Physical therapy follows, playing a vital role in improving muscle strength and mobility for long-term management and patient quality of life.

The market is divided into three categories based on Drug Class: Carbonic Anhydrase Inhibitors, Beta-Blockers, and Potassium Supplements. Carbonic anhydrase inhibitors are prioritized for their effectiveness in managing periodic paralysis episodes. Beta-blockers follow, addressing cardiac arrhythmias commonly seen in Andersen-Tawil Syndrome. Potassium supplements hold third priority, essential for correcting hypokalemia and stabilizing muscle and cardiac function in patients.

Andersen Tawil Syndrome Treatment Market- Geographical Insights

North America dominates the Andersen-Tawil Syndrome Treatment Market, driven by robust healthcare infrastructure and increased funding for rare disease research. The region benefits from initiatives like the Rare Disease Clinical Research Network (RDCRN), supported by the National Institutes of Health (NIH), which has facilitated over 70 collaborative studies on genetic disorders. The U.S. also witnessed a key partnership in 2023 between a leading pharmaceutical company and a biotech firm to develop novel potassium channel modulators aimed at addressing periodic paralysis associated with Andersen-Tawil Syndrome. Europe follows closely, with the European Medicines Agency (EMA) granting orphan drug designation to several investigational therapies. In Asia-Pacific, rising healthcare awareness and government support in countries like Japan, where the Orphan Drug Act encourages rare disease treatment development, are boosting market prospects. Furthermore, the launch of a telemedicine platform by a prominent healthcare provider in Australia has increased patient access to specialists, especially in rural regions, supporting better disease management.

Andersen Tawil Syndrome Treatment Market- Competitive Landscape:

The Andersen-Tawil Syndrome Treatment Market is marked by strong competition, with North America emerging as the leading region due to significant R&D investments and the presence of major pharmaceutical players. In 2023, a U.S.-based biotech company announced a strategic merger with a European firm to accelerate the development of potassium channel modulators, a promising treatment for periodic paralysis linked to Andersen-Tawil Syndrome. Additionally, collaborations between academic institutions and industry leaders have resulted in over 40 clinical trials focused on novel genetic therapies. Europe also plays a crucial role, with several pharmaceutical companies receiving orphan drug designations from the EMA, boosting the region's competitive edge. Meanwhile, in the Asia-Pacific, a Japanese firm recently launched a groundbreaking gene therapy platform targeting rare genetic disorders, enhancing its market position. These initiatives, coupled with the increasing adoption of telemedicine platforms globally, underscore the dynamic and competitive nature of the Andersen-Tawil Syndrome Treatment Market.

Recent Developments:

In April 2021, Karo Pharma Aktiebolag acquired Teva Pharmaceuticals to expand its European OTC portfolio and rare disease research. Sun Pharmaceutical Industries Ltd. acquired a 66% stake in Trikaal Mediinfotech and AWACS through its subsidiary, ABCD Technologies LLP.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medication
  • Physical Therapy

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Carbonic Anhydrase Inhibitors
  • Beta-Blockers
  • Potassium Supplements

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Research Institutes

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Andersen Tawil Syndrome Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Andersen Tawil Syndrome Treatment Market Snippet by Treatment Type
    • 2.1.2. Andersen Tawil Syndrome Treatment Market Snippet by Drug Class
    • 2.1.3. Andersen Tawil Syndrome Treatment Market Snippet by Route of Administration
    • 2.1.4. Andersen Tawil Syndrome Treatment Market Snippet by End-User
    • 2.1.5. Andersen Tawil Syndrome Treatment Market Snippet by Country
    • 2.1.6. Andersen Tawil Syndrome Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Andersen Tawil Syndrome Treatment Key Market Trends

  • 3.1. Andersen Tawil Syndrome Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Andersen Tawil Syndrome Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Andersen Tawil Syndrome Treatment Market Opportunities
  • 3.4. Andersen Tawil Syndrome Treatment Market Future Trends

4. Andersen Tawil Syndrome Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Andersen Tawil Syndrome Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Andersen Tawil Syndrome Treatment Market Landscape

  • 6.1. Andersen Tawil Syndrome Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Andersen Tawil Syndrome Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 7.1.2. Medication
    • 7.1.3. Physical Therapy

8. Andersen Tawil Syndrome Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 8.1.2. Carbonic Anhydrase Inhibitors
    • 8.1.3. Beta-Blockers
    • 8.1.4. Potassium Supplements

9. Andersen Tawil Syndrome Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous

10. Andersen Tawil Syndrome Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Research Institutes

11. Andersen Tawil Syndrome Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Andersen Tawil Syndrome Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Andersen Tawil Syndrome Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. Bayer AG
    • 12.2.5. Bristol-Myers Squibb Company
    • 12.2.6. Eisai Co., Ltd.
    • 12.2.7. F. Hoffmann-La Roche AG
    • 12.2.8. GlaxoSmithKline plc
    • 12.2.9. Johnson & Johnson Services, Inc.
    • 12.2.10. Merck & Co., Inc.
    • 12.2.11. Mylan N.V.
    • 12.2.12. Novartis AG
    • 12.2.13. Pfizer Inc.
    • 12.2.14. Sanofi S.A.
    • 12.2.15. Takeda Pharmaceutical Company Limited
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us